Cargando…

ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status

Only few drugs have shown activity in patients with advanced soft-tissue and the median overall survival is only 18 months. Alterations of genes involved in the DNA damage repair pathway have been associated with sarcoma risk and prognosis. ATR plays a crucial role in maintaining genomic integrity b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laroche-Clary, Audrey, Chaire, Vanessa, Verbeke, Stéphanie, Algéo, Marie-Paule, Malykh, Andrei, Le Loarer, François, Italiano, Antoine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198496/ https://www.ncbi.nlm.nih.gov/pubmed/32366852 http://dx.doi.org/10.1038/s41598-020-63294-z

Ejemplares similares

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
por: Laroche-Clary, Audrey, et al.
Publicado: (2017)

Prognostic impact of circulating tumor cells in patients with soft‐tissue sarcomas: a prospective study
por: Blanchi, Julie, et al.
Publicado: (2023)

LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications
por: Ben-Ami, Eytan, et al.
Publicado: (2020)

PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53
por: Grellety, Thomas, et al.
Publicado: (2015)

MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications
por: Spalato-Ceruso, M, et al.
Publicado: (2023)

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis
por: Lawlor, Rita T., et al.
Publicado: (2019)

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
por: Laroche-Clary, A, et al.
Publicado: (2015)

The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype
por: Amorim, João P., et al.
Publicado: (2016)

Single-molecule analysis of subtelomeres and telomeres in Alternative Lengthening of Telomeres (ALT) cells
por: Abid, Heba Z., et al.
Publicado: (2020)

Alternative lengthening of telomeres (ALT) in cancer stem cells in vivo
por: Bojovic, Bojana, et al.
Publicado: (2014)

Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells
por: Zhao, Shuang, et al.
Publicado: (2019)

The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT)
por: Sohn, Eric J., et al.
Publicado: (2023)

Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT)
por: De Vitis, Marco, et al.
Publicado: (2018)

Alternative lengthening of telomeres (ALT) cells viability is dependent on C-rich telomeric RNAs
por: Rosso, Ilaria, et al.
Publicado: (2023)

Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)
por: Kusuma, Frances Karla, et al.
Publicado: (2023)

GSK3-beta as a candidate therapeutic target in soft tissue sarcomas
por: Verbeke, S., et al.
Publicado: (2021)

ALT control, delete: FANCM as an anti-cancer target in Alternative Lengthening of Telomeres
por: O’Rourke, Julienne J, et al.
Publicado: (2019)

MEDB-68. Analysis of telomeres length and Alternative Lengthening of Telomeres (ALT) in molecular subgroups of infant medulloblastoma
por: Buttarelli, Francesca Romana, et al.
Publicado: (2022)

TCGA Pan-Cancer Genomic Analysis of Alternative Lengthening of Telomeres (ALT) Related Genes
por: Armendáriz-Castillo, Isaac, et al.
Publicado: (2020)

ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats
por: Frank, Lukas, et al.
Publicado: (2022)

Potential clinical treatment prospects behind the molecular mechanism of alternative lengthening of telomeres (ALT)
por: Sun, Haolu, et al.
Publicado: (2023)

High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies
por: Toulmonde, Maud, et al.
Publicado: (2020)

Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications
por: Fourneaux, Benjamin, et al.
Publicado: (2016)

The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)
por: Lu, Robert, et al.
Publicado: (2019)

Epigenetic Characteristics of Human Subtelomeres Vary in Cells Utilizing the Alternative Lengthening of Telomeres (ALT) Pathway
por: Toubiana, Shir, et al.
Publicado: (2021)

Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
por: Luchini, Claudio, et al.
Publicado: (2021)

Alternative Lengthening of Telomeres Is Rare in Canine Histiocytic Sarcoma
por: Kreilmeier-Berger, Theresa, et al.
Publicado: (2023)

Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition
por: Deeg, Katharina I., et al.
Publicado: (2016)

Gene expression profiling improves prognostication by nomogram in patients with soft‐tissue sarcomas
por: Crombé, Amandine, et al.
Publicado: (2022)

Author Correction: The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)
por: Lu, Robert, et al.
Publicado: (2019)

Antitumor Effects of PRMT5 Inhibition in Sarcomas
por: Verbeke, Stéphanie, et al.
Publicado: (2023)

MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies
por: Roy, Shomereeta, et al.
Publicado: (2020)

Telomere clustering drives ALT
por: Min, Jaewon, et al.
Publicado: (2019)

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin
por: Laroche, Audrey, et al.
Publicado: (2015)

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
por: Falcinelli, Marta, et al.
Publicado: (2023)

Alternative lengthening of telomeres: remodeling the telomere architecture
por: Conomos, Dimitri, et al.
Publicado: (2013)

Alternative Lengthening of Telomeres and Mediated Telomere Synthesis
por: Hou, Kailong, et al.
Publicado: (2022)

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting
por: Dadone-Montaudié, Bérengère, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6vldv3nsovn68r1k0r0c2lhe7p